Clinical progress in treatment of HER2 positive breast cancer with trastuzumab
10.3760/cma.j.issn.1673-422X.2010.08.012
- VernacularTitle:曲妥珠单抗治疗HER2+乳腺癌的临床进展
- Author:
Yan ZHU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Receptor,epidermal growth factor
- From:
Journal of International Oncology
2010;37(8):593-596
- CountryChina
- Language:Chinese
-
Abstract:
Clinical studies have shown that trastuzumab combined with chemotherapy can significantly improve survival in treatment of HER2-positive metastatic breast cancer as well as in the neoadjuvant and adjuvant therapy for HER2-positive early breast cancer. In patients with HER2-positive and hormone receptor-positive metastatic breast cancer, adding trastuzumab to endocrine therapy improves treatment efficacy. Resistance to trastuzumab may be reversed by incorporating other targeted therapeutic drugs. Patients can still benefit from continuing trastuzumab after their disease progresses.
